223 related articles for article (PubMed ID: 15650227)
21. Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1.
Stratov I; Dale CJ; Chea S; McCluskey J; Kent SJ
J Virol; 2005 Jun; 79(12):7728-37. PubMed ID: 15919925
[TBL] [Abstract][Full Text] [Related]
22. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
[TBL] [Abstract][Full Text] [Related]
23. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
[TBL] [Abstract][Full Text] [Related]
24. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
Chiappini E; Galli L; Zazzi M; de Martino M
J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
[TBL] [Abstract][Full Text] [Related]
25. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.
Cinque P; Presi S; Bestetti A; Pierotti C; Racca S; Boeri E; Morelli P; Carrera P; Ferrari M; Lazzarin A
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):377-83. PubMed ID: 11282006
[TBL] [Abstract][Full Text] [Related]
26. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
Winters MA; Merigan TC
Antimicrob Agents Chemother; 2005 Jul; 49(7):2575-82. PubMed ID: 15980322
[No Abstract] [Full Text] [Related]
27. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli.
Swiggard WJ; Baytop C; Yu JJ; Dai J; Li C; Schretzenmair R; Theodosopoulos T; O'Doherty U
J Virol; 2005 Nov; 79(22):14179-88. PubMed ID: 16254353
[TBL] [Abstract][Full Text] [Related]
28. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
Pomerantz RJ
Clin Infect Dis; 2002 Jan; 34(1):91-7. PubMed ID: 11731950
[TBL] [Abstract][Full Text] [Related]
29. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads.
Kieffer TL; Finucane MM; Nettles RE; Quinn TC; Broman KW; Ray SC; Persaud D; Siliciano RF
J Infect Dis; 2004 Apr; 189(8):1452-65. PubMed ID: 15073683
[TBL] [Abstract][Full Text] [Related]
30. Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo.
Lassen KG; Bailey JR; Siliciano RF
J Virol; 2004 Sep; 78(17):9105-14. PubMed ID: 15308706
[TBL] [Abstract][Full Text] [Related]
31. Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART.
Monno L; Punzi G; Scarabaggio T; Saracino A; Brindicci G; Fiore JR; Iambrenghi OC; Di Stefano M; Pastore G; Angarano G
J Med Virol; 2003 May; 70(1):1-9. PubMed ID: 12629636
[TBL] [Abstract][Full Text] [Related]
32. Establishment of latent HIV-1 infection of resting CD4(+) T lymphocytes does not require inactivation of Vpr.
Shen A; Siliciano JD; Pierson TC; Buck CB; Siliciano RF
Virology; 2000 Dec; 278(1):227-33. PubMed ID: 11112497
[TBL] [Abstract][Full Text] [Related]
33. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
34. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
[TBL] [Abstract][Full Text] [Related]
35. Frequency of protease and reverse transcriptase drug resistance mutations in naïve HIV-infected patients.
Valle-Bahena OM; Ramos-Jiménez J; Ortiz-López R; Revol A; Lugo-Trampe A; Barrera-Saldaña HA; Rojas-Martínez A
Arch Med Res; 2006 Nov; 37(8):1022-7. PubMed ID: 17045121
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 persistence in CD4+ T cells with stem cell-like properties.
Buzon MJ; Sun H; Li C; Shaw A; Seiss K; Ouyang Z; Martin-Gayo E; Leng J; Henrich TJ; Li JZ; Pereyra F; Zurakowski R; Walker BD; Rosenberg ES; Yu XG; Lichterfeld M
Nat Med; 2014 Feb; 20(2):139-42. PubMed ID: 24412925
[TBL] [Abstract][Full Text] [Related]
37. Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UNAIDS study.
Delgado E; León-Ponte M; Villahermosa ML; Cuevas MT; Deibis L; Echeverría G; Thomson MM; Pérez-Alvarez L; Osmanov S; Nájera R
AIDS Res Hum Retroviruses; 2001 May; 17(8):753-8. PubMed ID: 11429115
[TBL] [Abstract][Full Text] [Related]
38. Sustained appearance of drug resistance-associated mutations in HIV-1 CRF01_AE protease and reverse transcriptase derived from protease inhibitor-naive Thai patients.
Jullaksorn D; Boonchawalit S; Uttiyoung J; Soonthornsata B; Yowang A; Krathong N; Chautrakul S; Ikuta K; Roobsoong A; Kanitvittaya S; Sawanpanyalert P; Kameoka M
Southeast Asian J Trop Med Public Health; 2010 Mar; 41(2):347-57. PubMed ID: 20578518
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia).
Pérez-Alvarez L; Cuevas MT; Villahermosa ML; Pedreira JD; Manjón N; Herrero I; López-Calvo S; Delgado E; de Parga EV; Medrano L; Thomson MM; Taboada JA; Nájera R;
J Hum Virol; 2001; 4(1):35-8. PubMed ID: 11213931
[No Abstract] [Full Text] [Related]
40. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection.
Pierson TC; Zhou Y; Kieffer TL; Ruff CT; Buck C; Siliciano RF
J Virol; 2002 Sep; 76(17):8518-31. PubMed ID: 12163571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
